title: Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab.
abstract: OBJECTIVE
  To describe a case of juxtafoveal choroidal neovascularization (CNV) occurring in a patient affected by retinitis pigmentosa (RP), treated with intravitreal bevacizumab over a 12-month follow-up.
  
  
  METHODS
  A 66 year-old woman referred to our center for visual acuity deterioration was diagnosed as having classic juxtafoveal CNV associated with RP. The patient was treated with intravitreal bevacizumab, and was regularly monitored every month.
  
  
  RESULTS
  At the end of the 12-month follow-up, best corrected visual acuity changed from 20/200 to 20/100 in the affected eye. Five intravitreal bevacizumab injections were required to obtain the stabilization of the CNV.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab is effective in producing juxtafoveal CNV stabilization and visual acuity improvement in a patient affected by RP, over a 12-month follow-up. Future studies are required to ascertain the best therapeutic approach for CNV complicating RP.
authors.affiliation: Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milano, Italy.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Battaglia Parodi
authors.forename: Umberto
authors.initials: U
authors.lastname: De Benedetto
authors.forename: Karl Anders
authors.initials: KA
authors.lastname: Knutsson
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Scotti
authors.forename: Aloisa
authors.initials: A
authors.lastname: Librando
authors.forename: Francesco
authors.initials: F
authors.lastname: Bandello
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Iacono
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002829:Choroid / Q000098:blood supply*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D005584:Fovea Centralis / Q000098:blood supply*; D006801:Humans; D058449:Intravitreal Injections; D012174:Retinitis Pigmentosa / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D041622:Tomography, Optical; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab